SCPH vs. MCRB, CRVS, GNLX, RENB, IMAB, ACET, CTXR, KPTI, RGLS, and RPTX
Should you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Seres Therapeutics (MCRB), Corvus Pharmaceuticals (CRVS), Genelux (GNLX), Renovaro (RENB), I-Mab (IMAB), Adicet Bio (ACET), Citius Pharmaceuticals (CTXR), Karyopharm Therapeutics (KPTI), Regulus Therapeutics (RGLS), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
scPharmaceuticals has lower revenue, but higher earnings than Seres Therapeutics. scPharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -327.29%. scPharmaceuticals' return on equity of 0.00% beat Seres Therapeutics' return on equity.
Seres Therapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.
Seres Therapeutics received 367 more outperform votes than scPharmaceuticals when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 66.24% of users gave scPharmaceuticals an outperform vote.
In the previous week, Seres Therapeutics had 1 more articles in the media than scPharmaceuticals. MarketBeat recorded 5 mentions for Seres Therapeutics and 4 mentions for scPharmaceuticals. Seres Therapeutics' average media sentiment score of 1.35 beat scPharmaceuticals' score of 0.87 indicating that scPharmaceuticals is being referred to more favorably in the news media.
Seres Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 437.92%. scPharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 399.34%. Given scPharmaceuticals' higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than scPharmaceuticals.
59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are owned by institutional investors. 5.1% of Seres Therapeutics shares are owned by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Seres Therapeutics beats scPharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get scPharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
scPharmaceuticals Competitors List
Related Companies and Tools
